Evogene (EVGN) Projected to Post Quarterly Earnings on Wednesday

Evogene (NASDAQ:EVGN – Get Free Report) is expected to announce its Q1 2026 results before the market opens on Wednesday, May 20th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $0.35 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 20, 2026 at 9:00 AM ET.

Evogene (NASDAQ:EVGN – Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter. Evogene had a negative return on equity of 121.44% and a negative net margin of 214.57%.The business had revenue of $0.31 million during the quarter.

Get Evogene alerts:

Evogene Trading Down 2.0%

Shares of NASDAQ:EVGN opened at $0.76 on Wednesday. The stock’s 50-day moving average price is $0.80 and its two-hundred day moving average price is $0.98. Evogene has a 12-month low of $0.72 and a 12-month high of $2.42. The firm has a market cap of $6.64 million, a price-to-earnings ratio of -0.65 and a beta of 1.39.

Institutional Trading of Evogene

A number of hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC boosted its stake in Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after buying an additional 36,206 shares during the last quarter. Jane Street Group LLC boosted its stake in Evogene by 58.0% in the 1st quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Evogene in the 4th quarter worth about $25,000. 10.40% of the stock is owned by institutional investors and hedge funds.

About Evogene

(Get Free Report)

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.

Featured Articles

• Five stocks we like better than Evogene
• Navy Catalyst Ignites Odysight’s Growth Engine
• AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
• Axon Surged After Earnings and Is Still Down Over 50% From Highs
• The Event That Could Redefine Apple’s Summer Rally

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.